Use of model systems to understand the etiology of fragile X-associated primary ovarian insufficiency (FXPOI)

Journal of Neurodevelopmental Disorders

Volumn 6, Issue 1, 2014, Pages

  Sherman, Stephanie L ^a   Curnow, Eliza C ^b   Easley, Charles A ^a   Jin, Peng ^a   Hukema, Renate K ^c   Tejada, Maria Isabel ^d   Willemsen, Rob ^c   Usdin, Karen ^e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

CGG repeat; Fertility; Fragile X syndrome; Premature ovarian failure; Primary ovarian insufficiency; Repeat expansion disorder

Indexed keywords

ESTRADIOL; FOLLITROPIN; FRAGILE X MENTAL RETARDATION PROTEIN; LUTEINIZING HORMONE; MESSENGER RNA;

5' UNTRANSLATED REGION; ALLELE; CELL NUCLEUS INCLUSION BODY; CORPUS LUTEUM; DNA METHYLATION; DROSOPHILA MELANOGASTER; ESTROGEN DEFICIENCY; FEMALE SUBFERTILITY; FMR1 GENE; FRAGILE X ASSOCIATED PRIMARY OVARIAN INSUFFICIENCY; FRAGILE X SYNDROME; FRUIT FLY MODEL; GENE; GENE EXPRESSION; GENETIC BACKGROUND; GRANULOSA CELL; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HYPERGONADOTROPIC HYPOGONADISM; MODEL; MODIFIER GENE; MORPHOLOGY; MOUSE MODEL; NON INVASIVE PROCEDURE; NONHUMAN; OVARY FOLLICLE; OVARY FUNCTION; PHENOTYPE; PLURIPOTENT STEM CELL; PREMATURE OVARIAN FAILURE; PRIMATE MODEL; PRIORITY JOURNAL; RAT MODEL; REVIEW; TRINUCLEOTIDE REPEAT; UBIQUITINATION;

EID: 84956580634     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1186/1866-1955-6-26     Document Type: Review

References (83)

1. Sherman SL: Seminars in genetics: premature ovarian failure in the fragile X syndrome. Am J Med Genet 2000, 97:189-195.
2. De Caro JJ, Dominguez C, Sherman SL: Reproductive health of adolescent girls who carry the FMR1 premutation: expected phenotype based on current knowledge of fragile X-associated primary ovarian insufficiency. Ann N Y Acad Sci 2008, 1135:99-111.
3. Sullivan SD, Welt C, Sherman S: FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med 2011, 29:299-307.
4. Welt CK, Smith PC, Taylor AE: Evidence of early ovarian aging in fragile X premutation carriers. J Clin Endocrinol Metab 2004, 89:4569-4574.
5. Murray A, Ennis S, MacSwiney F, Webb J, Morton NE: Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet 2000, 8:247-252.
6. Rohr J, Allen EG, Charen K, Giles J, He W, Dominguez C, Sherman SL: Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum Reprod 2008, 23:1220-1225.
7. Sullivan AK, Marcus M, Epstein MP, Allen EG, Anido AE, Paquin JJ, Yadav-Shah M, Sherman SL: Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005, 20:402-412.
8. Spath MA, Feuth TB, Allen EG, Smits AP, Yntema HG, van Kessel AG, Braat DD, Sherman SL, Thomas CM: Intra-individual stability over time of standardized anti-Müllerian hormone in FMR1 premutation carriers. Hum Reprod 2011, 26:2185-2191.
9. Hundscheid RD, Braat DD, Kiemeney LA, Smits AP, Thomas CM: Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives. Hum Reprod 2001, 16:457-462.
10. Welt CK: Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf) 2008, 68:499-509.
11. Wittenberger MD, Hagerman RJ, Sherman SL, McConkie-Rosell A, Welt CK, Rebar RW, Corrigan EC, Simpson JL, Nelson LM: The FMR1 premutation and reproduction. Fertil Steril 2007, 87:456-465.
12. Streuli I, Fraisse T, Ibecheole V, Moix I, Morris MA, de Ziegler D: Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency. Fertil Steril 2009, 92:464-470.
13. Allen EG, Sullivan AK, Marcus M, Small C, Dominguez C, Epstein MP, Charen K, He W, Taylor K, Sherman SL: Examination of reproductive aging milestones among women who carry the FMR1 premutation. Hum Reprod 2007, 22:2142-2152.
14. Gallagher JC: Effect of early menopause on bone mineral density and fractures. Menopause 2007, 14:567-571.
15. Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, Paraskevaidis EA, Sideris DA, Tsatsoulis A, Chrousos GP, Michalis LK: Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004, 89:3907-3913.
16. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT: Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006, 13:265-279.
17. Jacobsen BK, Heuch I, Kvale G: Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 2003, 157:923-929.
18. Mondul AM, Rodriguez C, Jacobs EJ, Calle EE: Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005, 162:1089-1097.
19. van der Stege JG, Groen H, van Zadelhoff SJ, Lambalk CB, Braat DD, van Kasteren YM, van Santbrink EJ, Apperloo MJ, Weijmar Schultz WC, Hoek A: Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 2008, 15:23-31.
20. Tassone F, Beilina A, Carosi C, Albertosi S, Bagni C, Li L, Glover K, Bentley D, Hagerman PJ: Elevated FMR1 mRNA in premutation carriers is due to increased transcription. RNA 2007, 13:555-562.
21. Kenneson A, Zhang F, Hagedorn CH, Warren ST: Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 2001, 10:1449-1454.
22. Allen EG, He W, Yadav-Shah M, Sherman SL: A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet 2004, 114:439-447.
23. Peprah E, He W, Allen E, Oliver T, Boyne A, Sherman SL: Examination of FMR1 transcript and protein levels among 74 premutation carriers. J Hum Genet 2010, 55:66-68.
24. Garcia-Alegria E, Ibanez B, Minguez M, Poch M, Valiente A, Sanz-Parra A, Martinez-Bouzas C, Beristain E, Tejada MI: Analysis of FMR1 gene expression in female premutation carriers using robust segmented linear regression models. RNA 2007, 13:756-762.
25. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ: Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001, 57:127-130.
26. Ennis S, Ward D, Murray A: Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. EurJ Hum Genet 2006, 14:253-255.
27. Spath MA, Feuth TB, Smits AP, Yntema HG, Braat DD, Thomas CM, van Kessel AG, Sherman SL, Allen EG: Predictors and risk model development for menopausal age in fragile X premutation carriers. Genet Med 2011, 13:643-650.
28. Tejada MI, Garcia-Alegria E, Bilbao A, Martinez-Bouzas C, Beristain E, Poch M, Ramos-Arroyo MA, Lopez B, Fernandez Carvajal I, Ribate MP, Ramos F: Analysis of the molecular parameters that could predict the risk of manifesting premature ovarian failure in female premutation carriers of fragile X syndrome. Menopause 2008, 15:945-949.
29. Bione S, Benedetti S, Goegan M, Menditto I, Marozzi A, Ferrari M, Toniolo D: Skewed X-chromosome inactivation is not associated with premature ovarian failure in a large cohort of Italian patients. Am J Med Genet A 2006, 140:1349-1351.
30. Rodriguez-Revenga L, Madrigal I, Badenas C, Xuncla M, Jimenez L, Mila M: Premature ovarian failure and fragile X female premutation carriers: no evidences for a skewed X-chromosome inactivation pattern. Menopause 2009, 16:944-949.
31. Spath MA, Nillesen WN, Smits AP, Feuth TB, Braat DD, van Kessel AG, Yntema HG: X chromosome inactivation does not define the development of premature ovarian failure in fragile X premutation carriers. Am J Med Genet A 2010, 152A:387-393.
32. Hunter JE, Epstein MP, Tinker SW, Charen KH, Sherman SL: Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet Epidemiol 2008, 32:553-559.
33. Hoffman GE, Le WW, Entezam A, Otsuka N, Tong ZB, Nelson L, Flaws JA, McDonald JH, Jafar S, Usdin K: Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency. J Histochem Cytochem 2012, 60:439-456.
34. Lu C, Lin L, Tan H, Wu H, Sherman SL, Gao F, Jin P, Chen D: Fragile X premutation RNA is sufficient to cause primary ovarian insufficiency in mice. Hum Mol Genet 2012, 21:5039-5047.
35. Ascano M Jr, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, Langlois C, Munschauer M, Dewell S, Hafner M, Williams Z, Ohler U, Tuschl T: FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 2012, 492:382-386.
36. Ferder I, Parborell F, Sundblad V, Chiauzzi V, Gomez K, Charreau EH, Tesone M, Dain L: Expression of fragile X mental retardation protein and Fmr1 mRNA during folliculogenesis in the rat. Reprod Abstr Ser 2013, 145:335-343.
37. Entezam A, Biacsi R, Orrison B, Saha T, Hoffman GE, Grabczyk E, Nussbaum RL, Usdin K: Regional FMRP deficits and large repeat expansions into the full mutation range in a new fragile X premutation mouse model. Gene 2007, 395:125-134.
38. Peier AM, Nelson DL: Instability of a premutation-sized CGG repeat in FMR1 YAC transgenic mice. Genomics 2002, 80:423-432.
39. Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, Nelson DL: (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 2000, 9:1145-1159.
40. 98 repeat in the Fmr1 promoter. Hum Mol Genet 2001, 10:1693-1699.
41. Brouwer JR, Huizer K, Severijnen LA, Hukema RK, Berman RF, Oostra BA, Willemsen R: CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem 2008, 107:1671-1682.
42. Willemsen R, Hoogeveen-Westerveld M, Reis S, Holstege J, Severijnen LA, Nieuwenhuizen IM, Schrier M, van Unen L, Tassone F, Hoogeveen AT, Hagerman PJ, Mientjes EJ, Oostra BA: The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet 2003, 12:949-959.
43. The Dutch-Belgian Fragile X Consortium: Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994, 78:23-33.
44. Lin Y, Tang C, He H, Duan R: Activation of mTOR ameliorates fragile X premutation rCGG repeat-mediated neurodegeneration. PloS one 2013, 8:e62572.
45. Spradling A, Drummond-Barbosa D, Kai T: Stem cells find their niche. Nature 2001, 414:98-104.
46. Lin H: Stem cells: to be and not to be. Nature 2003, 425:353-355.
47. Spradling AC, de Cuevas M, Drummond-Barbosa D, Keyes L, Lilly M, Pepling M, Xie T: The Drosophila germarium: stem cells, germ line cysts, and oocytes. Cold Spring Harb Symp Quant Biol 1997, 62:25-34.
48. Wong MD, Jin Z, Xie T: Molecular mechanisms of germline stem cell regulation. Annu Rev Genet 2005, 39:173-195.
49. Lin H: Cell biology of stem cells: an enigma of asymmetry and self-renewal. J Cell Biol 2008, 180:257-260.
50. Yang L, Duan R, Chen D, Wang J, Jin P: Fragile X mental retardation protein modulates the fate of germline stem cells in Drosophila. Hum Mol Genet 1814-1820, 2007:16.
51. Garcia Arocena D, Breece KE, Hagerman PJ: Distribution of CGG repeat sizes within the fragile X mental retardation 1 (FMR1) homologue in a non-human primate population. Hum Genet 2003, 113:371-376.
52. Deelen W, Bakker C, Halley DJ, Oostra BA: Conservation of CGG region in FMR1 gene in mammals. Am J Med Genet 1994, 51:513-516.
53. Eichler EE, Hammond HA, Macpherson JN, Ward PA, Nelson DL: Population survey of the human FMR1 CGG repeat substructure suggests biased polarity for the loss of AGG interruptions. Hum Mol Genet 1995, 4:2199-2208.
54. Zhong N, Yang W, Dobkin C, Brown WT: Fragile X gene instability: anchoring AGGs and linked microsatellites. Am J Hum Genet 1995, 57:351-361.
55. Zwaka TP, Thomson JA: Homologous recombination in human embryonic stem cells. Nat Biotechnol 2003, 21:319-321.
56. Urbach A, Schuldiner M, Benvenisty N: Modeling for Lesch-Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells 2004, 22:635-641.
57. Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, Cohen P, Smith A: The ground state of embryonic stem cell self-renewal. Nature 2008, 453:519-523.
58. Shiozawa S, Kawai K, Okada Y, Tomioka I, Maeda T, Kanda A, Shinohara H, Suemizu H, James Okano H, Sotomaru Y, Sasaki E, Okano H: Gene targeting and subsequent site-specific transgenesis at the beta-actin (ACTB) locus in common marmoset embryonic stem cells. Stem Cells Dev 2011, 20:1587-1599.
59. Tong C, Li P, Wu NL, Yan Y, Ying QL: Production of p53 gene knockout rats by homologous recombination in embryonic stem cells. Nature 2010, 467:211-213.
60. Khan IF, Hirata RK, Russell DW: AAV-mediated gene targeting methods for human cells. Nat Protoc 2011, 6:482-501.
61. Khan IF, Hirata RK, Wang PR, Li Y, Kho J, Nelson A, Huo Y, Zavaljevski M, Ware C, Russell DW: Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther 2010, 18:1192-1199.
62. Asuri P, Bartel MA, Vazin T, Jang JH, Wong TB, Schaffer DV: Directed evolution of adeno-associated virus for enhanced gene delivery and gene targeting in human pluripotent stem cells. Mol Ther 2012, 20:329-338.
63. Bouhali K, Dipietromaria A, Fontaine A, Caburet S, Barbieri O, Bellessort B, Fellous M, Veitia RA, Levi G: Allelic reduction of Dlx5 and Dlx6 results in early follicular depletion: a new mouse model of primary ovarian insufficiency. Hum Mol Genet 2011, 20:2642-2650.
64. Kang Y, Cheng MJ, Xu CJ: Secretion of oestrogen from murine-induced pluripotent stem cells co-cultured with ovarian granulosa cells in vitro. Cell Biol Int 2011, 35:871-874.
65. Yang X, Zhou Y, Peng S, Wu L, Lin HY, Wang S, Wang H: Differentially expressed plasma microRNAs in premature ovarian failure patients and the potential regulatory function of mir-23a in granulosa cell apoptosis. Reproduction 2012, 144:235-244.
66. Hayashi K, Ogushi S, Kurimoto K, Shimamoto S, Ohta H, Saitou M: Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. Science 2012, 338:971-975.
67. Jin P, Duan R, Qurashi A, Qin Y, Tian D, Rosser TC, Liu H, Feng Y, Warren ST: Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 2007, 55:556-564.
68. Sellier C, Rau F, Liu Y, Tassone F, Hukema RK, Gattoni R, Schneider A, Richard S, Willemsen R, Elliott DJ, Hagerman PJ, Charlet-Berguerand N: Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. EMBO J 2010, 29:1248-1261.
69. Sellier C, Freyermuth F, Tabet R, Tran T, He F, Ruffenach F, Alunni V, Moine H, Thibault C, Page A, Tassone F, Willemsen R, Disney MD, Hagerman PJ, Todd PK, Charlet-Berguerand N: Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep 2013, 3:869-880.
70. Kuyumcu-Martinez NM, Wang GS, Cooper TA: Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 2007, 28:68-78.
71. Qurashi A, Li W, Zhou JY, Peng J, Jin P: Nuclear accumulation of stress response mRNAs contributes to the neurodegeneration caused by fragile X premutation rCGG repeats. PLoS Genet 2011, 7:e1002102.
72. Sofola OA, Jin P, Qin Y, Duan R, Liu H, de Haro M, Nelson DL, Botas J: RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007, 55:565-571.
73. Tian B, White RJ, Xia T, Welle S, Turner DH, Mathews MB, Thornton CA: Expanded CUG repeat RNAs form hairpins that activate the double-stranded RNA-dependent protein kinase PKR. RNA (New York, NY) 2000, 6:79-87.
74. Handa V, Saha T, Usdin K: The fragile X syndrome repeats form RNA hairpins that do not activate the interferon-inducible protein kinase, PKR, but are cut by Dicer. Nucleic Acids Res 2003, 31:6243-6248.
75. Samaraweera SE, O'Keefe LV, van Eyk CL, Lawlor KT, Humphreys DT, Suter CM, Richards RI: Modeling and analysis of repeat RNA toxicity in Drosophila. Methods Mol Biol 2013, 1017:173-192.
76. Ladd PD, Smith LE, Rabaia NA, Moore JM, Georges SA, Hansen RS, Hagerman RJ, Tassone F, Tapscott SJ, Filippova GN: An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 2007, 16:3174-3187.
77. Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA, Nan Z, Forster C, Low WC, Schoser B, Somia NV, Clark HB, Schmechel S, Bitterman PB, Gourdon G, Swanson MS, Moseley M, Ranum LP: Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA 2011, 108:260-265.
78. Todd PK, Oh SY, Krans A, He F, Sellier C, Frazer M, Renoux AJ, Chen KC, Scaglione KM, Basrur V, Elenitoba-Johnson K, Vonsattel JP, Louis ED, Sutton MA, Taylor JP, Mills RE, Charlet-Berguerand N, Paulson HL: CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 2013, 78:440-455.
79. Chang MC, DeCaro JJ, Zheng M, Gearing M, Shubeck L, Sherman SL, Welt CK: Ovarian histopathological and ubiquitin-immunophenotypic features in fragile X-associated primary ovarian insufficiency: a study of five cases and selected controls. Histopathology 2011, 59:1018-1023.
80. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, Jacquemont S, Leehey M, Hagerman PJ: Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002, 125:1760-1771.
81. Adhikari D, Flohr G, Gorre N, Shen Y, Yang H, Lundin E, Lan Z, Gambello MJ, Liu K: Disruption of Tsc2 in oocytes leads to overactivation of the entire pool of primordial follicles. Mol Hum Reprod 2009, 15:765-770.
82. Adhikari D, Liu K: mTOR signaling in the control of activation of primordial follicles. Cell Cycle 2010, 9:1673-1674.
83. Yu J, Yaba A, Kasiman C, Thomson T, Johnson J: mTOR controls ovarian follicle growth by regulating granulosa cell proliferation. PloS one 2011, 6:e21415.